BRCA1 and cancer: A subsequent study used publicly available transcriptional profiling data to demonstrate that BRD4 inhibition modulates a previously validated HR defect gene signature [84], though finding minimal impact on BRCA1 or RAD51 expression in cell lines of multiple cancer types.